Last reviewed · How we verify
nab-paclitaxel combined with carboplatin
Nab-paclitaxel is a chemotherapy medication that works by inhibiting cell division, while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication.
Nab-paclitaxel is a chemotherapy medication that works by inhibiting cell division, while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication. Used for Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | nab-paclitaxel combined with carboplatin |
|---|---|
| Also known as | paclitaxel combined with carboplatin |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University |
| Drug class | Taxane chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nab-paclitaxel is a microtubule inhibitor that binds to tubulin and prevents the formation of microtubules, thereby inhibiting cell division. Carboplatin, on the other hand, is a DNA-damaging agent that forms platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Approved indications
- Non-small cell lung cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (PHASE3)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: